Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of EC-MPS in Renal Transplant Recipients
NCT00238966Phase 4Completed
- Sponsor
- Novartis
- Start
- Nov 2002
- Primary completion
- Apr 2005
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in kidney transplant rejection, sponsored by Novartis. Primary endpoint: Safety and tolerability based on adverse events at 6 months. Started Nov 2002; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00238966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238966.